ZA914135B - Method of treating impotence - Google Patents

Method of treating impotence

Info

Publication number
ZA914135B
ZA914135B ZA914135A ZA914135A ZA914135B ZA 914135 B ZA914135 B ZA 914135B ZA 914135 A ZA914135 A ZA 914135A ZA 914135 A ZA914135 A ZA 914135A ZA 914135 B ZA914135 B ZA 914135B
Authority
ZA
South Africa
Prior art keywords
treating impotence
relieving
male
erectile impotence
impotence
Prior art date
Application number
ZA914135A
Other languages
English (en)
Inventor
George Mclean Milne
Mclean Milne George
Michael Grant Wyllie
Grant Wyllie Michael
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ZA914135B publication Critical patent/ZA914135B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Harvester Elements (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Tone Control, Compression And Expansion, Limiting Amplitude (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
ZA914135A 1990-05-31 1991-05-30 Method of treating impotence ZA914135B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53149490A 1990-05-31 1990-05-31

Publications (1)

Publication Number Publication Date
ZA914135B true ZA914135B (en) 1993-01-27

Family

ID=24117862

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA914135A ZA914135B (en) 1990-05-31 1991-05-30 Method of treating impotence

Country Status (15)

Country Link
EP (1) EP0459666B1 (de)
JP (1) JP2522609B2 (de)
KR (1) KR930010582B1 (de)
AT (1) ATE113839T1 (de)
AU (1) AU620282B2 (de)
CA (1) CA2043440C (de)
DE (1) DE69105040T2 (de)
DK (1) DK0459666T3 (de)
HU (1) HU208076B (de)
IE (1) IE63837B1 (de)
IL (1) IL98258A (de)
MY (1) MY106528A (de)
NZ (1) NZ238339A (de)
PT (1) PT97785B (de)
ZA (1) ZA914135B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4223800A1 (de) * 1992-07-20 1994-01-27 Cassella Farbwerke Mainkur Ag Verwendung von 1.2.5-Oxadiazol-2-oxiden zur Behandlung erektiler Dysfunktionen
ATE190843T1 (de) * 1993-02-10 2000-04-15 Bmra Corp Bv Zubereitungen zur behandlung von impotenz, die ein alpha-1 inhibitor und ein alpha-2 inhibitor enthalten
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
NZ297278A (en) 1994-11-16 1999-06-29 Synaptic Pharma Corp 4-aryl dihydropyrimidine derivatives end medicaments
US6268369B1 (en) 1994-11-16 2001-07-31 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
JPH10505611A (ja) * 1995-03-14 1998-06-02 ヴィヴァス・インコーポレーテッド 勃起機能不全を予防するための方法およびキット
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US6228861B1 (en) 1995-11-16 2001-05-08 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
CZ358598A3 (cs) 1996-05-10 1999-03-17 Icos Corporation Karbolinové deriváty
US6245773B1 (en) 1996-05-16 2001-06-12 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
US6172066B1 (en) 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
ES2282997T3 (es) * 1996-12-20 2007-10-16 Heumann Pcs Gmbh Nueva forma polimorfa de mesilato e doxazosina (forma iii).
EP0849264A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von doxazosinmesylat (Form I)
EP0849265A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von Doxazosin-Mesylat (Form II)
NZ504487A (en) * 1997-12-16 2002-11-26 Pfizer Prod Inc Combination of alpha-adrenergic antagonists and cGMP elevators for the treatment of impotence
DE19800214A1 (de) * 1998-01-06 1999-07-15 Knoll Ag Verfahren zur Herstellung von Doxazosin-Mcsylat in einer als Form A bezeichneten Kristallmodifikation und ein Zwischenprodukt dafür
US6268377B1 (en) * 1998-09-28 2001-07-31 Merck & Co., Inc. Method for treating androgen-related conditions
RU2135195C1 (ru) * 1998-12-17 1999-08-27 Овсюк Валерий Григорьевич Способ получения материала, содержащего клетки предстательной железы, материал, содержащий клетки предстательной железы, и способы лечения фиброматоза матки, хронического простатита и нарушений мужской половой функции методом трансплантации
US6274585B1 (en) 1998-12-23 2001-08-14 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6680323B2 (en) 1998-12-23 2004-01-20 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
GB0008332D0 (en) * 2000-04-04 2000-05-24 Pfizer Ltd Treament
US6521647B2 (en) 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
WO2001085171A1 (en) * 2000-05-12 2001-11-15 Novalar Pharmaceuticals, Inc. Local anesthetic methods and kits
US6720324B2 (en) 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925837A (en) * 1984-09-14 1990-05-15 Synthelabo Pharmaceutical compositions

Also Published As

Publication number Publication date
CA2043440C (en) 1996-07-30
JPH04235917A (ja) 1992-08-25
IL98258A (en) 1996-01-31
HU911810D0 (en) 1991-12-30
DE69105040D1 (de) 1994-12-15
PT97785A (pt) 1992-02-28
KR910019618A (ko) 1991-12-19
EP0459666A2 (de) 1991-12-04
IE911842A1 (en) 1991-12-04
IE63837B1 (en) 1995-06-14
NZ238339A (en) 1997-07-27
DK0459666T3 (da) 1994-12-05
IL98258A0 (en) 1992-06-21
PT97785B (pt) 1999-01-29
MY106528A (en) 1995-06-30
JP2522609B2 (ja) 1996-08-07
HUT58520A (en) 1992-03-30
ATE113839T1 (de) 1994-11-15
EP0459666B1 (de) 1994-11-09
EP0459666A3 (en) 1992-06-03
HU208076B (en) 1993-08-30
AU7807791A (en) 1991-12-05
AU620282B2 (en) 1992-02-13
CA2043440A1 (en) 1991-12-01
KR930010582B1 (ko) 1993-10-30
DE69105040T2 (de) 1995-03-23

Similar Documents

Publication Publication Date Title
ZA914135B (en) Method of treating impotence
CA2213339A1 (en) Method of treating adenosine depletion
EP0509019A4 (en) Treatment of human retroviral infections with 2',3'-dideoxyinosine
HU9302366D0 (en) Conjugates of interferons and method for producing them
GR3018009T3 (en) Use of gamma-hydroxybutyric acid salts for preparing pharmaceutical compositions for use in the treatment of alcoholism, and the compositions obtained.
CA2263561A1 (en) Thienopyrimidines
EP0550006A3 (en) Use of n-acyl derivatives of aminoalcohols for the manufacture of a medicament for the treatment of pathologies involving mast cells
GB9116054D0 (en) Preparation of fatty acid medicaments
AU8091787A (en) The use of paroxetine to treat pain
HU9203288D0 (en) Method for producing a compound of medical effect
GR1002329B (el) Μεθοδος για την παραγωγη αλατων κλαβουλανικου οξεος.
HU9403383D0 (en) Diamine salts of clavulanic acid
EP0362847A3 (de) Verwendung von Etoperidon zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von männlicher Impotenz
GR3021813T3 (en) Method of treating alopecia
WO1999059628A3 (en) Combination therapy for the treatment of tumors
GR3021003T3 (en) Antineoplastic effect potentiator and antineoplastic agent
WO1991015466A3 (en) Aminopolycarboxylic acid chelating agents
ZA953500B (en) Methods for treating neurofibromatosis
UA29461C2 (uk) Засіб для лікування амілоїдозу, спосіб лікування амілоїдозу
GR3029726T3 (en) Use of a therapeutic compound for the treatment of bronchitis
HUT59307A (en) Process for producing pharmaceutical compositions comprising zofenopril and suitable for treating arthritis
CA2188871A1 (en) Method for Treating Psoriasis
EP0539516A4 (de)
EP0260790A3 (de) Verwendung von Pinacidil zur Behandlung von Inkontinenz
RU93044256A (ru) Способ лечения саркоидоза